Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Genomics: Clinical Implementation » UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

Dec 13, 2019
|
staff reporter

NEW YORK – Researchers from the Institute of Cancer Research, London and the Royal Marsden NHS Foundation Trust have presented data demonstrating that blood-based genotyping assays can accurately detect specific biomarkers and potentially be used to guide targeted treatment of metastatic breast cancer. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Even Bigger

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Got Into the Lab Machines

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Not Going to Pay

Science reports that a Dutch research funding agency is combating a ransomware attack.

Science Papers Present Haplotype-Resolved Genomes, MiRNA-Linked Complex Tied to Ribosomal Protein Production

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

What's Popular?

In Liquid Biopsy

  1. Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year

    Premium

  2. Personalis to Broaden Liquid Biopsy Footprint With Minimal Residual Disease Testing

    Premium

  3. Guardant Health Begins First Foray Into Early-Stage Cancer With Commercial MRD Test Launch

    Premium

  4. Natera Revenues Grow 35 Percent in Q4

  5. Personal Genome Diagnostics to Build Commercial Infrastructure, Drive Partnerships With New Funding

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.